Artiva Biotherapeutics (NASDAQ:ARTV) Issues Earnings Results, Misses Estimates By $0.02 EPS

Artiva Biotherapeutics (NASDAQ:ARTV) announced its quarterly earnings results on Monday. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.02), FiscalAI reports.

Artiva Biotherapeutics Price Performance

Shares of ARTV stock traded up $0.07 during trading hours on Monday, hitting $4.22. The stock had a trading volume of 939,952 shares, compared to its average volume of 473,325. The firm has a market capitalization of $206.32 million, a PE ratio of -1.28 and a beta of 2.68. Artiva Biotherapeutics has a twelve month low of $2.96 and a twelve month high of $14.53. The stock’s 50 day moving average is $7.23 and its 200 day moving average is $7.95.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ARTV shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Needham & Company LLC downgraded shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Jefferies Financial Group lowered Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a report on Thursday, October 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Monday, October 19th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.80.

Insider Buying and Selling at Artiva Biotherapeutics

In other news, insider Subhashis Banerjee sold 8,222 shares of Artiva Biotherapeutics stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total value of $98,746.22. Following the transaction, the insider directly owned 142,047 shares of the company’s stock, valued at $1,705,984.47. The trade was a 5.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Christopher Horan sold 10,340 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total transaction of $70,725.60. Following the completion of the sale, the insider owned 312,744 shares of the company’s stock, valued at approximately $2,139,168.96. This trade represents a 3.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 137,048 shares of company stock valued at $1,086,167. 1.80% of the stock is currently owned by insiders.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.